Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency

Remy S. Petersen; Lauré M. Fijen; Laurens E. Franssen; Josephine M. I. Vos; Danny M. Cohn

doi:10.1016/j.jacig.2024.100322

Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency

Remy S. Petersen^*
, Lauré M. Fijen
, Laurens E. Franssen
, Josephine M. I. Vos
, Danny M. Cohn

^*Corresponding author for this work

Amsterdam UMC
Jeroen Bosch Ziekenhuis
Sanquin Blood Supply Foundation

Research output: Contribution to journal › Article › Academic › peer-review

27 Downloads (Pure)

Abstract

Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

Original language	English
Article number	100322
Journal	Journal of Allergy and Clinical Immunology: Global
Volume	3
Issue number	4
DOIs	https://doi.org/10.1016/j.jacig.2024.100322
Publication status	Published - 1 Nov 2024

Keywords

Acquired C1-inhibitor deficiency
angioedema
bradykinin
daratumumab
MGUS
monoclonal gammopathy

Access to Document

10.1016/j.jacig.2024.100322

Daratumumab-based-treatment-of-monoclonal-gammopathyassociated-angioedema-due-to-acquired-c1-inhibitor-deficiency.pdfFinal published version, 724 KBLicence: CC BY

Cite this

@article{4060f3ec865a477a8171d7dd0cecec81,

title = "Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency",

abstract = "Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.",

keywords = "Acquired C1-inhibitor deficiency, angioedema, bradykinin, daratumumab, MGUS, monoclonal gammopathy",

author = "Petersen, \{Remy S.\} and Fijen, \{Laur{\'e} M.\} and Franssen, \{Laurens E.\} and Vos, \{Josephine M. I.\} and Cohn, \{Danny M.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2024",

month = nov,

day = "1",

doi = "10.1016/j.jacig.2024.100322",

language = "English",

volume = "3",

journal = "Journal of Allergy and Clinical Immunology: Global",

issn = "2772-8293",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency

AU - Petersen, Remy S.

AU - Fijen, Lauré M.

AU - Franssen, Laurens E.

AU - Vos, Josephine M. I.

AU - Cohn, Danny M.

PY - 2024/11/1

Y1 - 2024/11/1

N2 - Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

AB - Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

KW - Acquired C1-inhibitor deficiency

KW - angioedema

KW - bradykinin

KW - daratumumab

KW - MGUS

KW - monoclonal gammopathy

UR - https://www.scopus.com/pages/publications/85202028085

U2 - 10.1016/j.jacig.2024.100322

DO - 10.1016/j.jacig.2024.100322

M3 - Article

C2 - 39282617

SN - 2772-8293

VL - 3

JO - Journal of Allergy and Clinical Immunology: Global

JF - Journal of Allergy and Clinical Immunology: Global

IS - 4

M1 - 100322

ER -

Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this